Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts

European Journal of Cancer

Volumn 41, Issue 8, 2005, Pages 1213-1222

  De Cesare, Michelandrea ^a   Perego, Paola ^a   Righetti, Sabina C ^a   Pratesi, Graziella ^a   Carenini, Nives ^a   Rivoltini, Licia ^a   Zupi, Gabriella ^b   Del Bufalo, Donatella ^b   Balsari, Andrea ^c   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bcl 2; Gimatecan; Melanoma; Oblimersen

Indexed keywords

ANTINEOPLASTIC AGENT; GIMATECAN; OBLIMERSEN; OLIGONUCLEOTIDE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TUMOR GROWTH; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 21144451944     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.001     Document Type: Article

References (34)

1. D.H. Lawson Update on the systemic treatment of malignant melanoma Semin Oncol 31 2004 33 37
2. J.B. Meric, O. Rixe, and D. Khayat Metastatic malignant melanoma Drugs Today 39 2003 17 38
3. G. Parmiani, C. Castelli, and P. Dalerba Cancer immunotherapy with peptide-based vaccines? What have we achieved? Where are we going? J Natl Cancer Inst 94 2002 805 818
4. L. Serrone, and P. Hersey The chemoresistance of human malignant melanoma: an update Melanoma Res 9 1999 51 58
5. M.S. Soengas, and S.W. Lowe Apoptosis and melanoma chemoresistance Oncogene 22 2003 3138 3151
6. J.C. Reed Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance Curr Opin Oncol 7 1995 541 546
7. U. Leiter, R.M. Schmid, and P. Kaskel Anti-apoptotic bcl-2 and bcl-xL in advanced malignant melanoma Arch Dermatol Res 292 2000 225 232
8. G. Pratesi, P. Perego, and F. Zunino Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy Biochem Pharmacol 61 2001 381 386
9. R.J. Klasa, A.M. Gillum, and R.E. Klem Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev 12 2002 193 213
10. R. Kim, M. Emi, and K. Tanabe Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy Cancer 101 2004 2491 2502
11. B. Jansen, V. Wacheck, and E. Heere-Ress Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy Lancet 356 2000 1728 1733
12. M.J. Millward, A.Y. Bedikian, and R.M. Conry Randomized multinational Phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of long-term survival Proc Am Soc Clin Oncol 708 2004 7505
13. J.F. Pizzolato, and L.B. Saltz The camptothecins Lancet 361 2003 2235 2242
14. S. Dallavalle, A. Ferrari, and B. Biasotto Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity J Med Chem 44 2001 3264 3274
15. G. Pratesi, M. De Cesare, and N. Carenini Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts Clin Cancer Res 8 2002 3904 3909
16. P. Perego, M. De Cesare, and P. De Isabella A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line Cancer Res 61 2001 6034 6037
17. M. De Cesare, G. Pratesi, and P. Perego Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin Cancer Res 61 2001 7189 7195
18. Y. Kawakami, S. Eliyahu, and K. Sakaguchi Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes J Exp Med 180 1994 347 352
19. C. Leonetti, A. Biroccio, and A. Candiloro Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma resistant to cisplatin Clin Cancer Res 5 1999 2588 2595
20. A. Iervolino, D. Trisciuoglio, and D. Ribatti Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity FASEB J 16 2002 1453 1455
21. L. Gatti, R. Supino, and P. Perego Apoptosis and growth arrest induced by platinum compound U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response Cell Death Diff 9 2002 1352 1359
22. G. Pratesi, C. Manzotti, and M. Tortoreto Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts Tumori 75 1989 60 65
23. A. Balsari, M. Tortoreto, and D. Besusso Combination of CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts Eur J Cancer 40 2004 1275 1281
24. A.M. Krieg CpG motifs in bacterial DNA and their immune effects Annu Rev Immunol 20 2002 709 760
25. J.A. Bush, and G. Li The role of Bcl-2 family members in the progression of cutaneous melanoma Clin Exp Met 20 2003 351 359
26. J.F. Pruijt, P. Verzaal, and R. van Os Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice PNAS 99 2002 6228 6233
27. L. Laterveer, I.J. Lindley, and M.S. Hamilton Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability Blood 85 1995 2269 2275
28. J.C. Lai, L. Benimetskaya, and R.M. Santella G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner Mol Cancer Ther 2 2003 1031 1043
29. R. Klasa, M.B. Bally, and R. Ng Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide Clin Cancer Res 6 2000 2492 2500
30. V. Wacheck, C. Krepler, and S. Strommer Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice Antisense Nucleic Acid Drug Dev 12 2002 359 367
31. D.E. Lopes de Menezes, N. Hudon, and N. McIntosh Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin Clin Cancer Res 6 2000 2891 2902
32. G. Petrangolini, G. Pratesi, and M. De Cesare Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts Mol Cancer Res 1 2003 863 870
33. D. Del Bufalo, D. Trisciuoglio, and M. Scarsella Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity Oncogene 22 2003 8441 8447
34. W. Hiraoka, N. Vazquez, and W. Nieves-Neira Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukaemia cells J Clin Invest 102 1998 1961 1968